CERo Therapeutics

Company snapshot

At CERo, we are expanding the armamentarium of engineered cell therapies to create a whole new class of innovative medicines for oncology. Armed with an understanding of cellular clearance and molecular immunology, we engineer cells to engage new and complementary cell elimination pathways to enable deeper and more sustained clinical responses to maximize wellness.

• 47 active pipeline program(s) linked via ClinicalTrials.gov.
• 14 US patent(s) indexed to this assignee profile.
• 47 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for CERo Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for CERo Therapeutics.

1. Jun 8, 2026 Clinical update

   IFCT-2003 — Phase 2

2. Jun 8, 2026 Clinical update

   IFCT-1904 — Phase 2

3. Jun 8, 2026 Clinical update

   FFCD 2006 NEORAF — Phase 2

4. Jun 8, 2026 Clinical update

   Fianlimab for Pleural mesothelioma — Phase 2

5. Jun 8, 2026 Clinical update

   Cyramza /ml concentrate for stomach cancer stage IV with me… — Phase 2

View all clinical trial activity →

• What is CERo Therapeutics?

  CERo Therapeutics is a biotech organization headquartered in South San Francisco, USA. It trades on NYSE under ticker CERO. Primary therapeutic focus areas include Non small cell lung cancer, oligometastatic hormone sensitive prostate cancer, Non small cell lung cancer, Poor gene

• Is CERo Therapeutics publicly traded?

  Yes. CERo Therapeutics is listed with ticker CERO on NYSE per SEC EDGAR records linked on this profile.

• What drugs does CERo Therapeutics develop or market?

  We link 84 drug profile(s) where CERo Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/cero-therapeutics-holdings-inc#company-drugs.

• What are the latest developments for CERo Therapeutics?

  In the last 12 months our linked public records show 47 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does CERo Therapeutics focus on?

  CERo Therapeutics focuses on Non small cell lung cancer, oligometastatic hormone sensitive prostate cancer, Non small cell lung cancer, Poor general status based on our analysis of their pipeline programs and drug development activities.